Yahoo
XETRA - Delayed Quote EUR

Carl Zeiss Meditec AG (AFX.DE)

34.98 +0.22 (+0.63%)
At close: October 30 at 5:37:33 PM GMT+1
Chart Range Bar
Loading chart for AFX.DE
  • Previous Close 34.76
  • Open 35.00
  • Bid 34.98 x 18700
  • Ask 35.30 x 15000
  • Day's Range 34.92 - 36.00
  • 52 Week Range 22.62 - 46.54
  • Volume 143,795
  • Avg. Volume 205,443
  • Market Cap (intraday) 3.062B
  • Beta (5Y Monthly) 1.33
  • PE Ratio (TTM) 25.17
  • EPS (TTM) 1.39
  • Earnings Date Dec 10, 2026
  • Forward Dividend & Yield 0.55 (1.58%)
  • Ex-Dividend Date Mar 27, 2026
  • 1y Target Est 26.93

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.

www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir

5,784

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

AFX.DE
10.58%
DAX P (^GDAXI)
5.42%

1-Year Return

AFX.DE
17.97%
DAX P (^GDAXI)
7.05%

3-Year Return

AFX.DE
53.01%
DAX P (^GDAXI)
75.44%

5-Year Return

AFX.DE
78.75%
DAX P (^GDAXI)
64.56%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 562.72M
Earnings 55.03M
Profit Margin 9.78%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
200M
400M
600M
0.0%
2.0%
4.0%
6.0%
8.0%

Analyst Insights

View More

Analyst Price Targets

18.10 Low
26.93 Average
34.98 Current
35.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.57%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    2.18B

  • Net Income Avi to Common (ttm)

    121.51M

  • Diluted EPS (ttm)

    1.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    23.9M

  • Total Debt/Equity (mrq)

    27.56%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: